Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW1911 in healthy volunteers
NCT05803902Phase 1Completed
- Sponsor
- Mabwell
- Start
- Dec 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 9MW1911 in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis (AD) (8 arms), sponsored by Mabwell. Primary endpoints: Adverse Event at Day 113 and Serious Adverse Event at Day 113. Started Dec 2021; status: completed.
02
Drugs
9MW1911
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05803902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803902.